$68.18
1.90% today
Nasdaq, Feb 05, 04:16 pm CET
ISIN
US2183521028
Symbol
CORT

Corcept Therapeutics Incorporated. Stock price

$66.91
+15.25 29.52% 1M
+32.40 93.89% 6M
+16.52 32.78% YTD
+45.44 211.64% 1Y
+47.50 244.72% 3Y
+53.87 413.11% 5Y
+63.89 2,115.56% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.36 0.54%
ISIN
US2183521028
Symbol
CORT
Sector
Industry

Key metrics

Market capitalization $7.01b
Enterprise Value $6.64b
P/E (TTM) P/E ratio 53.21
EV/FCF (TTM) EV/FCF 46.54
EV/Sales (TTM) EV/Sales 10.56
P/S ratio (TTM) P/S ratio 11.15
P/B ratio (TTM) P/B ratio 10.97
Revenue growth (TTM) Revenue growth 39.67%
Revenue (TTM) Revenue $628.56m
EBIT (operating result TTM) EBIT $143.36m
Free Cash Flow (TTM) Free Cash Flow $142.60m
Cash position $380.34m
EPS (TTM) EPS $1.26
P/E forward 47.54
P/S forward 10.12
EV/Sales forward 9.58
Short interest 21.79%
Show more

Is Corcept Therapeutics Incorporated. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Corcept Therapeutics Incorporated. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Corcept Therapeutics Incorporated. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Corcept Therapeutics Incorporated. forecast:

Buy
100%

Financial data from Corcept Therapeutics Incorporated.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
629 629
40% 40%
100%
- Direct Costs 9.80 9.80
61% 61%
2%
619 619
39% 39%
98%
- Selling and Administrative Expenses 243 243
37% 37%
39%
- Research and Development Expense 231 231
39% 39%
37%
145 145
44% 44%
23%
- Depreciation and Amortization 1.45 1.45
42% 42%
0%
EBIT (Operating Income) EBIT 143 143
46% 46%
23%
Net Profit 140 140
55% 55%
22%

In millions USD.

Don't miss a Thing! We will send you all news about Corcept Therapeutics Incorporated. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Corcept Therapeutics Incorporated. Stock News

Positive
FXEmpire
7 days ago
Corcept Therapeutics Incorporated (CORT) shares rise on treatment advances, Big Money buys.
Neutral
PRNewsWire
12 days ago
NEW YORK , Jan. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Inc. (NASDAQ: CORT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Positive
Seeking Alpha
14 days ago
Corcept's sole drug, Korlym, treats Cushing Syndrome, a more prevalent condition than previously known, driving strong revenue and profit growth. A new market for Corcept's medications, diabetics, is poised to take the company to the next level. Long-term goal is $3 billion revenue by 2029, driven by the new drug Relacorilant, which could expand market reach beyond Korlym.
More Corcept Therapeutics Incorporated. News

Company Profile

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Head office United States
CEO Joseph Belanoff
Employees 352
Founded 1998
Website www.corcept.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today